RxDoctor Payments Data

Karl Zimmerman, MD

Internal Medicine · Kennett Square, PANPI 1154439966

Payments from drug & device makers

$754in general payments, 2019–2025

Across 64 payments — averaging $11.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$367
  • AbbVie$213
  • Galderma Laboratories, L.p.$52
  • Merz North America, Inc.$41
  • Exact Sciences$35
  • Merck$18
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$754100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$754 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$306,081
Medicare patients
610
Services billed
4,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$101,520
JardianceEmpagliflozin48$49,879
XareltoRivaroxaban22$27,778
JanuviaSitagliptin Phosphate16$16,549
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,861
OzempicSemaglutide12$13,970
Rosuvastatin Calcium732$11,198
Tresiba Flextouch U-100Insulin Degludec19$10,326
Bydureon BciseExenatide Microspheres11$8,957
Praluent PenAlirocumab12$5,776
Novolog FlexpenInsulin Aspart18$4,382
SynthroidLevothyroxine Sodium73$4,373
PaxlovidNirmatrelvir/Ritonavir28$4,288
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$4,232
Ezetimibe137$4,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$14$105,808128 claims
MerckJanuvia$18$16,54916 claims
Novo NordiskOzempic$367$13,97012 claims
AbbVieSynthroid$213$4,37373 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Kennett Square

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →